OncoZenge is ending the year with a dual milestone. The company has submitted the Clinical Trial Application to the EMA for the pivotal phase III trial of BupiZenge. This operational achievement immediately triggered the third tranche of the company’s investment agreement, securing approximately 9,1 MSEK from strategic partner Sichuan Yangtian Bio-Pharmaceutical.
Read the full article at biostock.se:
OncoZenge advances BupiZenge with submitted CTA application and financing of SEK 9,1 million
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
© Modular Finance, source Nordic Press Releases